Researchers look at a gene called ERBB3 in glioblastoma
Original title: ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
Only the title is available, and it points to early research, not a treatment.
The short version
Scientists studied why some glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary tumors have too much of one gene, and whether that could be a weak spot.
What was studied. This study looked at glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary, a type of brain tumor. It looked at a gene called ERBB3 and a small switch called miR-205 that is turned off in these tumors.
What they found. The title says that when miR-205 is turned off, the tumor makes too much ERBB3. The tumor then reacts more to a growth signal called FGF, and its energy use is turned up. The title also says this may make the tumor open to treatments aimed at ERBB3. No summary of the study was given, so we do not know more details.
What this means, and what it doesn't
What it could mean: This may point to a new weak spot in some glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary tumors. In the future, it could help scientists look for treatments aimed at ERBB3.
What it doesn't mean: This does not mean there is a new treatment you can get. We only have the title, so we do not know how the study was done or how strong the results are. This looks like early research, far from everyday care. It is not a cure.
Source: PubMed, September 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.